Thank you for reaching out.
We’ll get back to you shortly.

Thank you for reaching out.
We’ll get back to you shortly.

Contact Us

How two researchers built the first genetics cohort of African children with autism

In 2015, Maria Chahrour, assistant professor of genetics and neuroscience at the University of Texas Southwestern Medical Center, began recruiting participants for studies on autism genetics out of her lab in Dallas. Among those who responded were parents and families who had recently immigrated from East Africa. They wanted to join the study, but they had some concerns and questions. So they asked if they could form their own group, in which they could help create the rules around how their data would be collected and used.

The collaboration that bloomed from those conversations created the first cohort of African children with autism — one that continues to grow and recruit families around the globe. Chahrour and her research partner, Leah Seyoum-Tesfa, spoke to Spectrum about their experiences forming the cohort and why increasing genetic diversity is vital for autism research. Listen to the interview here, or read the transcript below or download it here.
 

Spectrum: Could you both tell me who you are and what you do?

Maria Chahrour: Okay, well, hello, everyone, and thank you for having us. My name is Maria Chahrour. I’m an assistant professor at the Eugene McDermott Center and the neuroscience department at UT Southwestern Medical Center in Dallas. My lab studies the genetics of autism. We want to find the genes that cause autism and to study their function in depth, so that we can understand the specific biological pathways that they function in. And ultimately, we hope that our work will inform diagnosis and therapies.

Leah Seyoum-Tesfa: My name is Leah Seyoum-Tesfa. I’m originally from Ethiopia. I live in Irving, Texas. I am a mother of four children, two of whom are on the autism spectrum. In 2011, I started a nonprofit organization called Reaching Families Advocacy and Support Group. The purpose of the organization is to work with East African families who have children with intellectual and developmental disabilities. The organization started in Dallas, Texas, but it’s spread to — we have several organizations all over the United States. By training, I’m a nurse and I was a nurse practitioner. But I work, currently I’m an advocate. I support families in various systems — in the medical, educational, as well as the social systems. I also provide community awareness about developmental disabilities all over the United States.

I enjoy working with families; it’s a very rewarding thing to be able to support families’ access [to] early intervention and see the progress that children made throughout the year. And I support families also and their children to adulthood.

S: Thank you both for joining us, and you both do really interesting work, so I’m excited to talk about how you work together. Could you tell me a little bit about how you first met each other and came to work together?

MC: Sure. So in 2015 I moved to Dallas to start my own lab. And, as I said, a big part of our mission is to identify causative genes in families with autism with a specific focus on Dallas’ diverse population. So I had an ongoing human genetics study, recruiting local families with autism, and someone from the Ethiopian community in Dallas found out about the study. He actually works at UT Southwestern as well, and he saw one of our flyers and told Leah about the study, and then he introduced us. And I guess, Leah, I would love to hear how that initial reach-out happened for you and what was your impression when you heard about the study?

LS-T: When Dr. Bogale [Aredo], who was the president of [the Ethiopian Health Professionals Association] — I am a member of that group — reminded me about this study, and he saw the flyer and he showed it to me, I was very interested, because I’ve been concerned about the number of children that I see that have, from the East African community, primarily with autism. I’ve felt for a while that we are seeing a higher prevalence in our population. And we also see more-affected children in our population. So when he showed me the flyer, I was very interested because our community wants to find out why the higher prevalence and if there’s a genetic connection in our community. So I contacted Maria, and our collaboration started from there.

S: How did you come to collaborate rather than just participating in the study? Did you initially set out to want to have a bigger role in the study, or how did that relationship come about?

MC: I was really interested and impressed with everything that Leah had been doing and all of her efforts in her community. And you know, we had all these discussions about what she found with the higher prevalence of autism in East African families as she was working with the community. And we started having more and more of these meetings and discussions, and it sort of organically, I guess, grew into a collaboration. It was, I would say, a mutual learning journey for both of us, you know? I was really fascinated with all of the aspects that she was an expert in. And vice versa, I think.

LS-T: I agree with that. Yeah, it was a learning experience for me as well. Because other than the research that I have done as part of my training at the LEND program — I had attended a training in 2013, and my project was on the prevalence of autism in the East African community in Texas. I had taken data from the Texas Education Agency, and I had found that it was a higher prevalence. And this came when I met Maria; I was very interested in studying this further.

S: I think Maria had told me previously that once you wanted to include more people from your community in the study, that there were some questions that came up about participating, and it actually spawned its own separate cohort study instead. Can you tell me about some of those questions that came up? And then how that led to a separate study being made for the African community around autism?

MC: So, as I mentioned, you know, the two of us started meeting and discussing the study designs and what elements we had to take into consideration. So, specifically, the community’s concerns about privacy and data protection and the stigma associated with autism within the community. I visited the community center and church multiple times, spoke to family members about autism and genetics, and about the study that we were running. And, you know, myself and Leah, we answered their questions and addressed their concerns. And I would say, then, we took care of some logistics. Before I go into that maybe I’ll let Leah tell you a little bit more about the families’ specific concerns around these issues.

Maria Chahrour and Leah Seyoum-Tesfa at Maria's home.

LS-T: There’s a lot of stigma around it. And people are very careful to admit their children have autism, or a family member. Unfortunately, it’s associated with mental health issues, and somebody being crazy, or somebody being like an evil spirit. So the stigma around it was a big issue that we have to deal with, and I still deal with in the community. The other concern was lack of knowledge. They didn’t know what research would mean. It’s not something that we’ve participated [in] as a community in the DFW area, or even any area that I’m aware of as an immigrant community. So doing a study was something new.

S: And DFW, is that Dallas-Fort Worth?

LS-T: Dallas-Fort Worth, I’m sorry.

The other piece was, what is going to come with this study? What’s the outcome and what the data was going to be used for?

S: And so, what kind of things did you do, both in the recruiting and in the study design, to kind of allay those concerns?

MC: I would say we really had a lot of discussions. A critical part of this was just meeting with family members, addressing all of their questions, making sure that everyone is comfortable with everything we had in the study forms. Leah had reviewed all of the study forms. And we translated them into Amharic and Tigrinya. And then after we finalized all of these logistics, Leah announced the start of recruitment and enrollment to the community members and the families that she was supporting through the Reach foundation. I would say it took us about two years from when we initially met, to set everything up and have all of these really important and critical discussions with community members so that we can incorporate their feedback, before we actually started actively enrolling participants.

S: Wow, two years. That’s a long time.

MC: Yeah.

S: And so what has the recruitment process been like since then? You know, how many families have you been able to recruit and is it still ongoing? Catch me up to how it’s been going the last couple of years.

MC: This past year, it’s been really slow, of course, with everything that’s going on with the COVID-19 pandemic. But you know, so far we’ve enrolled 30 families, I would say, and that’s over 120 individuals, and it’s still very much ongoing and active.

When UT Southwestern shut down earlier in March, human subject research that did not involve a critical procedure was kind of put on hold. So we couldn’t bring in study participants for their research appointments. I think that was the main hit. But now, you know, we’re hoping that things are going to get better, and that we’re able to deal with all of these logistical issues. We’re all adapting, I would say.

S: So, Leah, you told us at the beginning about what Reach does. Can you tell me how that plays a role in the study that you do with Maria?

LS-T: I work by bringing community awareness. I go to several churches — before COVID. Now through Zoom, I do community awareness; I teach families about early signs of autism. And the purpose is to get early intervention. At that time, I do offer all the families an opportunity to participate in the study. And not all families are ready to do that. They’re still trying to accept that their child has autism. We’re also going through the difficult diagnostic process, finding a diagnostician and waiting on these long lines with the various providers. So it takes a little bit longer. I think within a year after the diagnosis, a lot of families will agree or decide to participate or not.

So the purpose, as I said, is to provide early intervention and help families, but as part of that I do explain to them about the research and the opportunity to join the research. Like I said, it’s not every family that chooses to participate. But some families are very interested; some choose to just do a genetic study through their pediatrician or specialist. But that’s how we are able to reach families. Now I do have — like I said, I started with families in [the] Dallas area — but I do have families, we even have some families in Europe, that live in Germany and I think other countries, that were able to participate in this study.

S: Wow. Do you have partners in Europe that sort of help with the recruitment there?

LS-T: No, I do 100 percent of the recruitment, families that I support through accessing interventions. We do have a heavy online presence, and through our website, and through our Facebook and other resources, we provide information. We have monthly educational meetings that are available to any families recorded. We teach them about various things about early intervention, about therapies, about [applied behavior analysis], about all kinds of things, dietary interventions. We have specialists that come and speak to families about, the bigger one is a lot of behavior support. Fortunately, we do have many community members that are in the profession that are able to share this information in Tigrinya and in Amharic that is very accessible to these families. So families from all over the world, we have families in Africa as well, in Asia; people, immigrants, families can access our educational information. And part of that educational information is we had Maria speak about the genetic study, and they can access that and reach Maria at UT Southwestern to participate in the study.

MC: Once we make contact with the families, you know, my study coordinator sort of arranges for the research appointment if they’re local, or otherwise we send them a study kit with instructions of what to do and how to actually collect samples and things like that.

S: And when you’re doing this global outreach, are you mostly focused on families from Ethiopia specifically?

MC: So we’re focusing on East African families, specifically from Ethiopia and Eritrea, although we’ve had Kenyan and Somali families participate as well. But the vast majority are from Ethiopia and Eritrea.

LS-T: We do support, actually, Kenyan families. There’s not a heavy presence in the DFW area. But we do have a mother that supports the Kenyan families, and through her we were able to recruit a few families I believe, but it’s heavy Ethiopian, Eritrean immigrant families in the DFW area.

S: And you have a partner in Ethiopia, correct? An organization there that you partner with?

MC: It sort of started as this part of our long-term capacity-building project for autism in Ethiopia. So I got to visit the Joy Autism Center in Addis Ababa in the summer of 2019. And I discussed our study with the center founder, Zemi Yenus. And as part of that trip, I also gave a talk and ran a workshop with colleagues on autism and autism genetics at the Bahir Dar University, and that was geared towards healthcare professionals. So Zemi is interested in collaborating with myself and Leah, but we haven’t actually started enrolling participants simply because of logistical issues that were caused by the pandemic and the recent political unrest. Of course, we are planning to expand our study and collaborate with colleagues and community partners in Ethiopia. That’s our long-term plan.

S: And so now that it’s been going on, the study’s been going on for a few years, what have you been hearing from families about their experience participating in the study?

MC: I believe they’re excited about the study. We’ve had a meeting after we completed the latest batch of sequencing to discuss our preliminary analysis with the community. And we’re planning for other community update meetings as we finalize our analysis. But I think Leah can speak more to the family’s impressions and how motivated they are to participate.

LS-T: The ones that have participated are very eager to know the results. They call me often and say, “What have we found? Where are we now?” They’re just eager to find out; the process was very easy. Maria really made it easy in that the kit was sent home; when we were drawing blood, the phlebotomist came to the home to draw the blood. And it was really a very smooth process for a lot of the families, even the ones in Europe. They told me the process was very easy. And we’re just waiting for the results. Everybody’s eager. We are realizing the prevalence; we’re seeing a lot of our friends and siblings also having children with autism. So that’s what we really need to know, if there is a genetic connection here.

S: I’m curious if you’ve seen any kind of shifts, like you mentioned that there’s some stigma in the community or just not being as familiar with research studies. Have you seen, anecdotally, shifts from people who have participated in any of those attitudes?

LS-T: You know, I see a change in that even families that have not participated in the study are now very interested in doing that. Initially, people were worried about what’s going to happen with the data — is my name is going to be available on [the] internet about my child having autism? — those kinds of concerns. But now that they know, and Maria has come and explained to us how the data is saved, there are more families interested. Because of COVID, there’s a lot going on with the disability community. COVID has been even harder. Families are struggling with kids not attending school. So it’s kind of been really hard. And then finding even somebody to diagnose the children during this time has been difficult.

But I’ve seen a shift. I’ve seen a shift in stigma, because there’s so many of us, many centers all over the United States, that we are going to the churches and talking about autism. We’re in a good place; I think we’re going in the right direction. Kids are getting help sooner.

S: It sounds like a really powerful community-based approach to doing this kind of science.

MC: Yes, yes, for sure.

LS-T: Definitely. Definitely.

S: And maybe we can talk a little bit about, you know, what you’re finding from the study. What kind of gaps is that filling for the science about autism?

MC: Populations in Africa are the most genetically diverse in the world and carry up to three times as many rare variants as, say, populations of European origin. And research so far on the genetics of autism has overwhelmingly focused on people of European ancestry. And, of course, although these studies are extremely valuable to our understanding of this complex genetics of autism, they don’t really capture the genetic diversity on the African continent. And this loss of genetic diversity in the current studies really limits our scope of understanding autism.

So because genomic studies so far have been largely focused on European populations and identifying autism variants in these European cohorts, the transferability of these findings to non-European populations is limited.

And then, of course, as genetic findings move into the clinic, this lack of diversity and lack of genetic data from non-European populations translates to healthcare disparities. So when a genetic diagnosis is made in the clinic, it’s vital to understand the variant in the context of ancestry, because the frequencies of some of these variants are population-specific.

So for clinical genetics to be equitable, it needs to be able to offer patients and their families interpretation that encompasses their specific ancestry. And as a genetics community, the community as a whole recognizes this need for diversity and the need to do more sequencing on the African continent to be able to understand variants in the context of ancestry, and is working to be more inclusive. An example of this, you know, there’s a big effort right now that’s focused on exactly doing this. And it’s the Human Heredity and Health in Africa, or the H3Africa consortium, which was conceived to address the paucity of genomics research in Africa. So I think we have a lot to learn from this. We have a lot to find and discover. And we have this amazing opportunity to do this now.

Maria Chahrour portrait

LS-T: We realize there’s a very heavy burden of more affected children in our community. I strongly believe in that. We’re seeing more kids in our community. Siblings — I have a lot of families that have two, three children somewhere on the spectrum. I myself have two kids on the autism spectrum, fraternal twins. So we are very eager to find out what is causing this high incidence of autism in our children. And hopefully, this research will answer some of our questions.

MC: I just want to add to that we are really interested and we set out to see: What is this genetic factor that’s predisposing the community to autism? And that’s sort of the big question that we’re going after.

S: When you say there’s a higher prevalence in the community, what kind of numbers would you say there are?

MC: Leah’s own work on public schools in the state of Texas showed that the prevalence is up to three times higher than the prevalence in the general non-African population. And also, there is one of the sites where the [Centers for Disease Control and Prevention] does the monitoring network for autism is in Minnesota, and they found that the prevalence of autism in the Somali population in Minnesota was, I believe, up to two to three times higher than the general population as well.

So there are all these findings that were pretty much from prevalence studies that were done on immigrant populations outside of Africa because, unfortunately, I believe there are only two prevalence studies for autism in Africa — one out of Uganda and one out of Nigeria. You know, of course, depending on who you ask, there might be other factors that influence or result in this higher prevalence. And of course, these prevalence studies on immigrant populations are smaller than what you would typically see from other prevalence studies. But we think it’s a start. We think that in the meantime, we can do something with the information that we already have. And you know, as a geneticist, I’m really interested in the genetic risk factors. Although we’re not eliminating other hypotheses, of course, but we’re testing our hypothesis that there is a genetic risk factor in this community

LS-T: And the study that I did, it wasn’t published, but it was part of my report. In the Amharic-speaking population, we saw 1 in 40. In the Tigrinya-speaking, we saw 1 in 51. And in the Ethiopic — they call it Ethiopic because there’s other languages spoken in Ethiopia, including Amharic, Tigrinya, Oromo — 1 in 22 children had autism.

And then in the whole Texas population, at that time is 1 in 167 children were identified — educational identification of autism, with my research. And then, as Maria mentioned, we reviewed a lot of studies that were done in Europe. And there’s also a study out of California that showed higher prevalence in immigrant families who have children with autism who are African American. The European studies looked in depth about East African families. There was also a New Zealand and Australian study that had higher prevalence in our community.

S: Wow, those are some very big discrepancies. Very big differences.

LS-T: There was, there was. And you know, the other thing is, this is in educationally identified children. They were looking at the children that are, they tend to identify the more affected children. And the kids that are less affected are not identified, even so in our community, because parents don’t want their children identified. If there’s a little bit of, you know, social problems, and the kids end up being verbal, they usually don’t want their kids identified. These are kids that have significant disability and are often educated separately in a self-contained classroom.

So we’re looking at even a much higher rate in our community, because we’re not always identifying all the children. This was, if you look at the Somali study in Minnesota, the first study came out in 2014. Those identified were 100 percent of those children had intellectual disability. Whereas a much lesser number of children in the Minnesota study of the other races had intellectual disability. What that tells me, and I think the researchers concluded, is that we’re not identifying those kids that are less affected in these communities. We’re just looking at those with intellectual disability that are easily identified in the school system.

MC: Yeah, yeah. So, you know, basically, we’re missing a lot of kids who are more mildly affected. And I think that, again, speaks to this really big need for doing comprehensive prevalence studies in Africa.

LS-T: Definitely, definitely.

S: And does your genetic study mostly then lean toward having people who have intellectual disability? Or are you also working to identify those less affected kids and get them in the study as well?

MC: So we do have kids on both ends of the spectrum, I would say. It’s because these families were primarily identified through Leah’s efforts in the Reach foundation, and she works with all kinds of kids on the spectrum. So, you know, we are enrolling everyone at this point, yeah.

LS-T: We do have the same, even people, families that come to me for help, usually have more affected children. These kids are identified early on; usually they’re all over the spectrum. But the older kids that are identified usually are more significantly affected that come to me for help.

S: So just thinking about the more broad need in the field to have greater diversity in genetic studies, are there any kind of lessons that you think you’ve learned in creating and working on this cohort that might inform other researchers about how to increase diversity in genetic studies?

MC: Yes, this is a big question. And we could both go on and on. So we certainly learned a lot. For one, we need to continue doing this and expand our study to enroll more participants and sequence more genomes. And the genetic diversity on the African continent can teach us a lot about the genetics of autism and about the biological pathways and mechanisms underlying the disorder.

We learned that there’s still a lot of stigma associated with having autism in many communities. And we need to really be diligent about removing that stigma and spreading the right information so that we can empower families to deal with this in their communities. And we need to listen to, understand and respect the communities’ concerns. And we need to work together. It has to be a true partnership between scientists and parents for us to be successful. We also learned that a lot of these families are facing and dealing with the burdens of autism without much support. So participating in research studies may not necessarily be a top priority when you don’t have access to basic services.

LS-T: Yeah. You said it really well, Maria. Families are struggling, caring for the kids and accessing resources. Sometimes research is not a priority for them. I think the fact that Maria was able to come and explain everything really well for us, that was very helpful. And she also had an opportunity to come back and update us about where the research is. And we were able to recruit more families after that.

I think just understanding their culture and the stigma around it was very good for Maria to understand and work with us [and make] research easy for the families. She accommodated the needs of the families, because it would have been very hard for the families to take their kids to have their blood drawn, the whole family; she made that very easier. And those things are very important. Making things very accessible for the families and continuing to communicate with them. It’s very important, especially for communities that are not, might not have a lot of knowledge about research.

S: Great. Well, this has been a really fascinating discussion about your work. I’m really curious to see where it goes in the next couple of years.

MC: Thank you. Yeah, we’re both really excited about this, and hopeful.

LS-T: And thank you for giving us the opportunity to share our research and about our concern in our community.

The post How two researchers built the first genetics cohort of African children with autism appeared first on Spectrum | Autism Research News.

related articles

User Pic

Beyond the bench: A conversation with Matthew Lerner

Matthew Lerner Associate professor, Stony Brook University Under normal circumstances...

User Pic

How to support Black scientists and clinicians in autism research

Desiree Jones Graduate student, University of Texas at Dallas David Mandell Professo...

User Pic

‘Theory of mind’ does not fade with age among autistic adults

Aging minds: Younger autistic people may have trouble interpreting others’ thoughts, bu...

User Pic

Community newsletter: Spectrum sparks a literature review; using frogs as models

In this week’s community newsletter, read about how Spectrum prompted a literature revi...

close  

google analytics policy

we may collect information about your computer, including your IP address, operating system and browser type, for system administration and in order to create reports. This is statistical data about our users' browsing actions and patters, and does not identify any individual.

The only cookies in use on our site are for Google Analytics. Google Analytis is aweb analytics tool that helps website owners understand how visitors engage with their website. GoogleAnalytics customers can view a variety of reports about how visitors interact with their website so that they can improve it.

Like many services, Google Analytics users first-party cookies to track visitor interactions as in our case, where they are used to collect information about how visitors use our site. We then use the information to compile reports and to help use improve our site.

Cookies contain information that is transferred to your computer's hard drive. These cookies are used to store information, such as the time that the current visit occured, whether the visitor has been to the site before and what site referred the visitor to the web page.

Google Analyticsw collets information anonymously. It reports website trends without identifying individual visitors. you can opt out of Google Analytics without affecting how your visit our site- for more information on opting our of being tracked by Google Analytics across all websites you use, visit this Google page

close  

hipaa privacy

Compleat KiDZ

THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY.

If you have any questions about this Notice of Privacy Practices, please contact our Privacy Officer, by telephone at (704) 824-7800 or in writing at 2675 Court Drive, Gastonia, NC 28054.
This Notice of Privacy Practices describes how we may use and disclose your protected health information to carry out treatment, payment or health care operations and for other purposes that are permitted or required by law. It also describes your rights to access and control your protected health information. Protected health information is information about you, including demographic information, that may identify you and that relates to your past, present or future physical or mental health or condition and related health care services.

A. WE MUST PROTECT YOUR PROTECTED HEALTH INFORMATION

We are required to abide by the terms of this Notice of Privacy Practices. We may change the terms of our Notice of Privacy Practices at any time. The new Notice of Privacy Practices will be effective for all protected health information that we maintain at that time. Upon your request, we will provide you with any revised Notice of Privacy Practices. You may request a revised version by calling or writing our Privacy Officer and requesting that a revised copy be sent to you in the mail or asking for one at the time of your next appointment.

B. USE AND DISCLOSURES OF PROTECTED HEALTH INFORMATION

Your protected health information may be used and disclosed by our office staff others outside of our office who are involved in your care and treatment for the purpose of providing health care services to you.
Your protected health information may also be used and disclosed to pay your health care bills and to support the operation of our practice.
Following are examples of the types of uses and disclosures of your protected health information that we are permitted to make. These examples are not meant to be exhaustive, but to describe the types of uses and disclosures that may be made by our office.

1. Treatment: We will use and disclose your protected health information to provide, coordinate, or manage your health care and any related services. This includes the coordination or management of your health care with another provider.
For example, we would disclose your protected health information, as necessary, to a home health agency that provides care to you. We will also disclose protected health information to other healthcare providers who may be treating you.
For example, your protected health information may be provided to a physician to whom you have been referred to ensure that the physician has the necessary information to diagnose or treat you. In addition, we may disclose your protected health information from time-to-time to other health care providers (e.g., a specialist or laboratory) who become involved in your care by providing assistance with your health care diagnosis or treatment to us.
2. Payment: We may use and disclose protected health information about you so that the treatment and services you receive at Compleat KiDZ may be billed to and payment may be collected from you, an insurance company, or a third party. This may include certain activities that your health insurance plan may undertake before it approves or pays for the health care services we recommend for you such as: making a determination of eligibility or coverage for insurance benefits, and reviewing services provided to you for medical necessity. For example, if you have a back injury, we may need to give your health plan information about your condition, supplies used, and services you received.
3. Healthcare Operations: We may use or disclose, as needed, your protected health information for healthcare operations. These uses and disclosures are necessary to run Compleat KiDZ and make sure that all of our patients receive quality care. For example, we ma)'use protected health information to review our treatment and services and to evaluate the performance of our staff in caring for you. We may also combine protected health information about many patients to decide what additional services Compleat KiDZ should offer, what services are not needed, and whether certain new treatments are effective. We may also disclose information to doctors, nurses, technicians, medical students, and other personnel for review and learning purposes, we may remove information that identifies you from this set of protected health information so others may use it to study health care and health care delivery without learning the identities of specific patients.
We may share your protected health information with third party "business associates" that perform various activities (for example, billing or transcription services) for our practice. Whenever an arrangement between our practice and a business associate involves the use or disclosure of your protected health information, we will have a written contract that contains terms that will protect the privacy of your protected health information.
We may use and / or disclose protected health information to contact you to, remind you about an appointment you have for treatment or medical care.
We may use or disclose your protected health information, as necessary, to provide you with information about treatment alternatives or other health--related benefits and services that may be of interest to you. You may contact our Privacy Officer to request that these materials not be sent to you.
4. Other Permitted and Required Uses and Disclosures That May Be Made Without Your Authorization or Opportunity to Agree and Object:
We may use or disclose your protected health information in the following situations without your authorization or providing you the opportunity to agree or object. These situations include:
(i) Required by Law: We may use or disclose your protected health information to the extent that the use or disclosure is required by law. The use or disclosure will be made in compliance with the law and will be limited d to the relevant requirements of the law. You will be notified, if required by law, of any such uses or disclosures.

(ii) Public Health: We may disclose your protected health information for public health activities and purposes to a public health authority that is permitted by law to collect or receive the information. For example, a disclosure may be made for the purpose of preventing or controlling disease, injury or disability.

(iii) Communicable Diseases: We may disclose your protected health information, if authorized by law, to a person who may have been exposed to a communicable disease or may otherwise be at risk of contracting or spreading the disease or condition.

(iv) Health Oversight: We may disclose protected health information to a health oversight agency for activities authorized by law, such as audits, investigations, and inspections. Oversight agencies seeking this information include government agencies t-rat oversee the health care system, government benefit programs, other government regulatory programs and civil rights laws.

(v) Abuse or Neglect: We may disclose your protected health information to a public health authority that is authorized by law to receive reports of child abuse or neglect. In addition, we may disclose your protected health information if we believe that you have been a victim of abuse, neglect or domestic violence to the governmental entity or agency authorized to receive such information. In this case, the disclosure will be made consistent with the requirements of applicable federal and state laws.

(vi) Legal Proceedings: We may disclose protected health information in the course of any judicial or administrative proceeding, in response to an order of a court or administrative tribunal (to the extent such disclosure is expressly authorized), or in certain conditions in response to a subpoena, discovery request or other lawful process.

(vii) Law Enforcement: We may also disclose protected health information, so long as applicable legal requirements are met, for law enforcement purposes, these law enforcement purposes include (1) legal processes and otherwise required by law, (2) limited information requests for identification and location purposes, (3) pertaining to victims of a crime, (4) suspicion that death has occurred as a result of criminal conduct, (5) in the event that a crime occurs on the premises of our practice, and (6) medical emergency (not on our premises) and it is likely that a crime has occurred.

(viii) Research: We may disclose your protected health information to researchers when their research has been approved by an institutional review board that has reviewed the research proposal and established protocols to ensure the privacy of your protected health information.

(ix) Criminal Activity: Consistent with applicable federal and state laws, we may disclose your protected health information, if we believe that the use or disclosure is necessary to prevent or lessen a serious and imminent threat to the health or safety of a person or the public. We may also disclose protected health information if it is necessary for law enforcement authorities to identify or apprehend an individual.

(x) Military Activity and National Security: When the appropriate conditions apply, we may use or disclose protected health information of individuals who are Armed Forces personnel (1) for activities deemed necessary by appropriate military command authorities; (2) for the purpose of a determination by the Department of Veterans Affairs of your eligibility for benefits, or (3) to foreign military authority if you are a member of that foreign military services. We may also disclose your protected health information to authorized federal officials for conducting national security and intelligence activities, including for the provision of protective services to the President or others legally authorized.

(xi) Workers' Compensation: We may disclose your protected health information as authorized to comply with workers' compensation laws and other similar legally established programs.
5. Other Permitted and Required Uses of Disclosures That Require Providing You the Opportunity to Agree or Object
We may use and disclose your protected health information in the following instances. You have the opportunity to agree or object to the use or disclosure of all or part of your protected health information. If you are not present or able to agree or object to the use or disclosure of the protected health information, then we may, using professional judgment, determine whether the disclosure is in your best interest.

Others Involved in Your Health Care or Payment for our Care:

Unless you object, we may disclose to a member of your family, a relative, a close friend or any other person you identify, your protected health information that directly relates to that person's involvement in your health care. If you are unable to agree or object to such a disclosure, we may disclose such information as necessary if we determine that it is in your best interest based on our professional judgment. We may use or disclose protected health information to notify or assist in notifying a family member, personal representative or any other person that is responsible for your care of your location, general condition or death. Finally, we may use or disclose your protected health information to an authorized public or private entity to assist in disaster relief efforts and to coordinate uses and disclosures to family or other individuals involved in your health care.
6. Uses and Disclosures of Protected Health Information Based upon Your Written Authorization Other uses and disclosures of your protected health information will be made only with your written authorization, unless otherwise permitted or required by law as described below. You may revoke this authorization in writing at any time. If you revoke your authorization, we will no longer use or disclose your protected health information for the reasons covered by your written authorization. Please understand that we are unable to take back any disclosures already made with your authorization.
C. YOUR RIGHTS
Following is a statement of your rights with respect to your protected health information and a brief description of how you may exercise these rights
1. You have the right to inspect and copy your protected health information
This means you may inspect and obtain a copy of protected health information about you for so long as we maintain the protected health information. You may obtain your medical record that contains medical and billing records and any other records that we use for making decisions about you. As permitted by federal or state law, we may charge you a reasonable copy fee for a copy of your records.
2. You have the right to request a restriction of your protected health information
This means you may ask us not to use or disclose any part of your protected health information for the purposes of treatment, payment or health care operations. You may also request that any part of your protected health information not be disclosed to family members or friends who may be involved in your care or for notification purposes as described in this Notice of Privacy Practices. Your request must state the specific restriction requested and to whom you want the restriction to apply.

We are not required to agree to a restriction that you may request. If we agree to the requested restriction, we may not use or disclose your protected health information in violation of that restriction unless it is needed to provide emergency treatment. With this in mind, please discuss any restriction you wish to request with your health provider.

You may request a restriction by making your request in writing to our Privacy Officer. In your request, you must tell us (1) what information you want to limit; (2) whether you want to limit our use, disclosure, or both; and (3) to whom you want the limits to apply, for example, disclosures to your spouse.
3. You have the right to request to receive confidential communications from us by alternative means or at an alternative location
We will accommodate reasonable requests. We may also condition this accommodation by asking you for information as to how payment will be handled or specification of an alternative address or other method of contact. We will not request an explanation from you as to the basis for the request. Please make this request in writing to our Privacy Officer.
4. Your may have right to amend your protected health information
This means you may request an amendment of protected health information about you in a designated record set for so long as we maintain this information. In certain cases, we may deny your request for an amendment. If we deny your request for amendment, you have the right to file a statement of disagreement with us and we may prepare a rebuttal to your statement and will provide you with a copy of any such rebuttal. Please contact our Privacy Officer if you have questions about amending your medical record.
5. You have the right to receive an accounting of certain disclosures we have made, if any, of your protected health information This right applies to disclosures for purposes other than treatment, payment or health care operations as described in this Notice of Privacy Practices. It excludes disclosures we may have made to you if you authorized us to make the disclosure, to family members or friends involved in your care, or for notification purposes, for national security or intelligence, to law enforcement (as provided in the privacy rule) or correctional facilities, as part of a limited data set disclosure. The right to receive this information is subject to certain exceptions, restrictions and limitations.
6. You have the right to obtain a paper copy of this notice from us
upon request, even if you have agreed to accept this notice electronically.
D. COMPLAINTS
You may complain to us or to the Secretary of Health and Human Services if you believe your privacy rights have been violated by us. You may file a complaint with us by notifying our Privacy Officer of your complaint. We will not retaliate against you for filing a complaint

You may contact our Privacy Officer at (704) 824-7800 for further information about the complaint process.

This notice was published and becomes effective on August l, 2011.